Eine Analyse von Popliteratur der Gegenwart

Aufgrund der nicht abnehmenden Popularität von zeitgenössischen Jugendromanen, insbesondere aus dem Fantasy-Genre, ist es nicht unerheblich, wenn diese Art der Literatur, die speziell für eine sehr junge und daher leicht beeinflussbare Zielgruppe vorgesehen ist, problematische Aspekte und Verhaltensweisen aufweist, die das Lesepublikum in seiner Wahrnehmung der zelebrierten, oft allerdings nur scheinbar starken, kompetenten Protagonistin manipulieren. Das geschieht, wenn diese Inhalte nicht als problematisch kenntlich gemacht, sondern romantisiert und verherrlicht werden, was auch die Leserschaft dazu verleitet, sie als tolerabel und wünschenswert aufzufassen und gerade in Bezug auf romantische Beziehungen im realen Leben mitunter nicht als die Warnsignale zu registrieren, die sie darstellen. Die vorliegende Masterarbeit beschäftigt sich daher damit, solche Aspekte und Verhaltensweisen im Rahmen von drei prominenten Kontexten (die Verharmlosung des aggressiven männlichen Gegenparts zugunsten der Liebesbeziehung; die Abwertung anderer weiblicher Figuren zugunsten der Protagonistin; die Herabsetzung, Stereotypisierung und Verklärung der Protagonistin) in acht zeitgenössischen deutschen Jugendromanen herauszuarbeiten. Dabei kommt sie zu dem Schluss, dass Werke wie diese, die für Jugendliche erwiesenermaßen weit mehr sind als flüchtige Unterhaltung, ein verfälschtes, schädliches Bild davon präsentieren, was es bedeutet, eine starke, unabhängige junge Frau zu sein. Damit ebnen sie mitunter den Weg für das bereits sehr reale Phänomen des Missbrauchs in Paarbeziehungen unter Jugendlichen, weshalb sich in Zukunft dringend etwas an dieser bisher objektiv durchaus erfolgreichen Art des Geschichtenerzählens ändern muss. Folgende Jugendromane werden analysiert: ‚Der Märchenerzähler‘ (2011) von Antonia Michaelis; ‚Light & Darkness‘ (2013) von Laura Kneidl; ‚Mein bester letzter Sommer‘ (2016) von Anne Freytag; ‚Das geheime Vermächtnis des Pan‘ (2013) von Sandra Regnier; ‚Conversion – Zwischen Tag und Nacht‘ (2016) von C. M. Spoerri u. Jasmina Romana Welsch; ‚Götterfunke – Liebe mich nicht‘ (2017) von Marah Woolf; ‚Warrior & Peace – Göttliches Blut‘ (2018) von Stella A. Tack; ‚Silberschwingen – Erbin des Lichts‘ (2018) von Emily Bold

Common misconceptions and myths about ovarian cancer causation: a national cross-sectional study from palestine

Abstract Background Women’s inability to recognize ovarian cancer (OC) causation myths to be incorrect may lead to behavioral changes that could distract them from actual risk factors and impact their treatment decision making. This study examined Palestinian women’s recognition of OC mythical causes, and explored factors associated with good recognition. Methods A national cross-sectional study was conducted. Adult Palestinian women were recruited from hospitals, primary healthcare facilities, and public areas in 11 governorates. The Cancer Awareness Measure-Mythical Causes Scale was modified and utilized for data collection. Awareness level was determined based on the number of myths around OC causation recognized to be incorrect: poor (0–4), fair (5–9), and good (10–13). Results A total of 5618 participants agreed and completed the questionnaire out of 6095 approached (response rate = 92.1%), and 5411 questionnaires were included in the final analysis. The most recognized food-related myth was ‘drinking from plastic bottles’ (n = 1370, 25.3%) followed by ‘eating burnt food’ (n = 1298, 24.0%). The least recognized food-related myth was ‘eating food containing additives’ (n = 611, 11.3%). The most recognized food-unrelated myth was ‘having a physical trauma’ (n = 2899, 53.6%), whereas the least recognized was ‘using mobile phones’ (n = 1347, 24.9%). Only 273 participants (5.1%) had good awareness of OC causation myths as incorrect. Earning higher monthly incomes as well as visiting governmental healthcare facilities were associated with a decrease in the likelihood of exhibiting good awareness. Conclusion The overall recognition of OC causation myths was low. Addressing mythical beliefs should be included in OC prevention strategies and public health interventions to improve women’s understanding of OC risk factors versus mythical causes

Anticipated time to seek medical advice for possible ovarian cancer symptoms and perceived barriers to early presentation among Palestinian women: a national cross-sectional study

Abstract Background Several factors contribute to delayed presentation with ovarian cancer (OC) symptoms including poor symptom awareness and barriers to seeking help. This study explored the anticipated time to seek medical advice for possible OC symptoms and its association with OC symptom awareness. In addition, it examined perceived barriers that may delay help-seeking among Palestinian women. Methods A cross-sectional study was conducted among adult women (≥ 18 years) recruited from hospitals, primary healthcare centers, and public spaces in 11 Palestinian governorates. A modified version of the OC awareness measure was used to collect data in face-to-face interviews. The questionnaire comprised three sections: sociodemographic details, awareness of 11 OC symptoms and time to seek medical advice, and barriers to early presentation. Results Of 6095 participants approached, 5618 completed the OCAM (response rate = 92.1%). The proportion of participants who would immediately seek medical advice for a possible OC symptom varied based on the symptom’s nature. For OC symptoms with pain, the proportion that reported immediate seeking of medical advice ranged from 7.9% for ‘persistent low back pain’ to 13.6% for ‘persistent pain in the pelvis’. For non-specific potential OC symptoms, the proportion that reported immediate seeking of medical advice ranged from 2.3% for ‘feeling full persistently’ to 15.8% for ‘increased abdominal size on most days’. Good OC symptom awareness was associated with higher likelihood of seeking medical advice within a week from recognizing 10 out of 11 OC symptoms. Emotional barriers were the most common barriers with ‘feeling scared’ as the most reported barrier (n = 1512, 52.4%). Displaying good OC symptom awareness was associated with a lower likelihood of reporting ≥ 4 emotional barriers (OR = 0.61, 95% CI: 0.38–0.98). Conclusion Participants with good OC symptom awareness were more likely to seek medical advice earlier and to display fewer emotional barriers. Establishing educational interventions to raise OC awareness may help in promoting earlier help-seeking and, thus, facilitate earlier diagnosis and improved prognosis

Additional file 1 of Common misconceptions and myths about ovarian cancer causation: a national cross-sectional study from palestine

Supplementary Material

Additional file 1 of Anticipated time to seek medical advice for possible ovarian cancer symptoms and perceived barriers to early presentation among Palestinian women: a national cross-sectional study

Additional file 1: Supplementary table 1. Characteristics of study participants

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo